Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Dalton

Showing results (11-20 of 375) with videos related to

Pageof 38
Sort By:
Annales De L'Institut Pasteur|October 1, 1972
Infection of neuronal and glial tissue "in vivo" by Langat, a group B arbovirusS Dalton
Cancer Treatment Reviews|May 10, 2003
The tumor microenvironment: focus on myelomaWilliam S Dalton
Cancer Control : Journal of the Moffitt Cancer Center|April 28, 2005
The "total cancer care" concept: linking technology and health careWilliam S Dalton
Seminars in Hematology|December 31, 1997
Mechanisms of drug resistance in hematologic malignanciesW S Dalton
Seminars in Oncology|February 1, 1993
Drug resistance modulation in the laboratory and the clinicW S Dalton
Seminars in Oncology|January 10, 2003
Drug resistance and drug development in multiple myelomaWilliam S Dalton
The Journal of the American Osteopathic Association|December 1, 1984
Peripartum cardiomyopathy: report of a caseL S Dalton
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res., 8: 3658-3668, 2002William S Dalton
The Medical Journal of Australia|September 9, 1978
MethadoneM S Dalton
Hematology/Oncology Clinics of North America|October 23, 1997
Alternative (non-P-glycoprotein) mechanisms of drug resistance in non-Hodgkin's lymphomaW S Dalton
Pageof 38

Showing results (11-20 of 375) with videos related to

Sort By:
Pageof 38
Annales De L'Institut Pasteur|October 1, 1972
Infection of neuronal and glial tissue "in vivo" by Langat, a group B arbovirusS Dalton
Cancer Treatment Reviews|May 10, 2003
The tumor microenvironment: focus on myelomaWilliam S Dalton
Cancer Control : Journal of the Moffitt Cancer Center|April 28, 2005
The "total cancer care" concept: linking technology and health careWilliam S Dalton
Seminars in Hematology|December 31, 1997
Mechanisms of drug resistance in hematologic malignanciesW S Dalton
Seminars in Oncology|February 1, 1993
Drug resistance modulation in the laboratory and the clinicW S Dalton
Seminars in Oncology|January 10, 2003
Drug resistance and drug development in multiple myelomaWilliam S Dalton
The Journal of the American Osteopathic Association|December 1, 1984
Peripartum cardiomyopathy: report of a caseL S Dalton
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res., 8: 3658-3668, 2002William S Dalton
The Medical Journal of Australia|September 9, 1978
MethadoneM S Dalton
Hematology/Oncology Clinics of North America|October 23, 1997
Alternative (non-P-glycoprotein) mechanisms of drug resistance in non-Hodgkin's lymphomaW S Dalton
Pageof 38